Table 2.
Biosimilar trastuzumab candidates in Phase III development
| Company/biosimilar | Clinical Trials.gov identifier | Population | Primary endpoint | Status |
|---|---|---|---|---|
| Celltrion/CT-P6 | NCT01084876 | MBC | ORR | Global phase III trial completed [11, 15] and applications for approval forthcoming |
| Biocon | N/A | N/A | N/A | Completed in India; results pending [16] |
| BIOCAD/BCD-022 | NCT01764022 | MBC | ORR PK | Enrollment open in Russia, India, and Belarus [17] |
| Amgen, Synthon, Actavis/ABP-90 | NCT01901146 | EBC | pCR | Enrollment temporarily halted [18] |
| Pfizer/PF-05280014 | N/A | MBC | N/A | Planned [14] |